Periodic fever syndromes.
Lachmann HJ.
Best Pract Res Clin Rheumatol. 2017 Aug;31(4):596-609. doi: 10.1016/j.berh.2017.12.001. Epub 2018 Jan 11.
The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors.
Zhan X, Li Q, Xu G, Xiao X, Bai Z.
Front Immunol. 2023 Jan 18;13:1109938. doi: 10.3389/fimmu.2022.1109938. eCollection 2022.
Systemic autoinflammatory diseases: Clinical state of the art.
Georgin-Lavialle S, Ducharme-Benard S, Sarrabay G, Savey L, Grateau G, Hentgen V.
Best Pract Res Clin Rheumatol. 2020 Aug;34(4):101529. doi: 10.1016/j.berh.2020.101529. Epub 2020 Jun 13.
Prevalence, Management, and Anaphylaxis Risk of Cold Urticaria: A Systematic Review and Meta-Analysis.
Prosty C, Gabrielli S, Le M, Ensina LF, Zhang X, Netchiporouk E, Ben-Shoshan M.
J Allergy Clin Immunol Pract. 2022 Feb;10(2):586-596.e4. doi: 10.1016/j.jaip.2021.10.012. Epub 2021 Oct 18.
Localized facial cold urticaria.
Patel R, Wolff A.
Ann Allergy Asthma Immunol. 2015 Jul;115(1):79-80. doi: 10.1016/j.anai.2015.04.001. Epub 2015 May 5.
Cold Urticaria Triggered After Treatment With Amoxicillin-Clavulanic Acid.
García-Paz V, Romero-Sánchez L, Otero-Alonso A, González-Rivas M, Fernández-Franco I, Vila Sexto L.
J Investig Allergol Clin Immunol. 2023 Dec 14;33(6):495-497. doi: 10.18176/jiaci.0907. Epub 2023 Apr 12.
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.
Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron K, Benseler S, Berard RA, Broderick L, Dedeoglu F, Diebold M, Durrant K, Ferguson P, Foell D, Hausmann JS, Jones OY, Kastner D, Lachmann HJ, Laxer RM, Rivera D, Ruperto N, Simon A, Twilt M, Frenkel J, Hoffman HM, de Jesus AA, Kuemmerle-Deschner JB, Ozen S, Gattorno M, Goldbach-Mansky R, Demirkaya E.
Arthritis Rheumatol. 2022 Jul;74(7):1102-1121. doi: 10.1002/art.42139. Epub 2022 May 27.
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.
Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron KS, Benseler S, Berard R, Broderick L, Dedeoglu F, Diebold M, Durrant KL, Ferguson P, Foell D, Hausmann J, Jones OY, Kastner DL, Lachmann HJ, Laxer RM, Rivera D, Ruperto N, Simon A, Twilt M, Frenkel J, Hoffman H, de Jesus AA, Kuemmerle-Deschner JB, Ozen S, Gattorno M, Goldbach-Mansky R, Demirkaya E.
Ann Rheum Dis. 2022 Jul;81(7):907-921. doi: 10.1136/annrheumdis-2021-221801. Epub 2022 May 27.
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders.
Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, Wang A, Tao J, Wang C, Liu Q, Jin T, Jiang W, Deng X, Zhou R.
J Exp Med. 2017 Nov 6;214(11):3219-3238. doi: 10.1084/jem.20171419. Epub 2017 Oct 11.
CAPS and NLRP3.
Booshehri LM, Hoffman HM.
J Clin Immunol. 2019 Apr;39(3):277-286. doi: 10.1007/s10875-019-00638-z. Epub 2019 May 10.
